AMPHASTAR PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.21 USD | -0.52% |
|
-0.59% | -31.75% |
| 05-08 | Transcript : Amphastar Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| 05-08 | Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 905.4 | 955.3 | 1,114 | 1,354 | 2,963 | 2,063 | - | - |
| Enterprise Value (EV) 1 | 905.4 | 955.3 | 1,114 | 1,354 | 2,963 | 2,485 | 2,283 | 2,052 |
| P/E ratio | 19.7 x | 670 x | 18.6 x | 16.1 x | 23.8 x | 10.8 x | 9.57 x | 8.18 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.81 x | 2.73 x | 2.55 x | 2.71 x | 4.6 x | 2.74 x | 2.45 x | 2.2 x |
| EV / Revenue | 2.81 x | 2.73 x | 2.55 x | 2.71 x | 4.6 x | 3.31 x | 2.71 x | 2.19 x |
| EV / EBITDA | 25.3 x | 16.8 x | 11.2 x | 9.21 x | 10.4 x | 8.34 x | 6.74 x | 5.24 x |
| EV / FCF | 4,374 x | - | - | 20.8 x | - | 16.8 x | 11.2 x | 8.92 x |
| FCF Yield | 0.02% | - | - | 4.81% | - | 5.96% | 8.89% | 11.2% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 46,938 | 47,504 | 47,849 | 48,331 | 47,907 | 48,866 | - | - |
| Reference price 2 | 19.29 | 20.11 | 23.29 | 28.02 | 61.85 | 42.21 | 42.21 | 42.21 |
| Announcement Date | 12/03/20 | 15/03/21 | 10/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 322.4 | 349.8 | 437.8 | 499 | 644.4 | 751.8 | 842.6 | 936.7 |
| EBITDA 1 | 35.73 | 56.75 | 99.1 | 147.1 | 283.9 | 298 | 338.7 | 391.8 |
| EBIT 1 | 18.66 | 36.26 | 76.9 | 121.8 | 245.8 | 259 | 293.7 | 342.2 |
| Operating Margin | 5.79% | 10.36% | 17.57% | 24.42% | 38.15% | 34.45% | 34.85% | 36.54% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | 250 | 276 | 330 |
| Net income 1 | - | 1.403 | 62.12 | 91.39 | 137.5 | 202.4 | 215.7 | 257.9 |
| Net margin | - | 0.4% | 14.19% | 18.31% | 21.34% | 26.92% | 25.6% | 27.54% |
| EPS 2 | 0.9800 | 0.0300 | 1.250 | 1.740 | 2.600 | 3.894 | 4.410 | 5.163 |
| Free Cash Flow 1 | 0.207 | - | - | 65.15 | - | 148 | 203 | 230 |
| FCF margin | 0.06% | - | - | 13.06% | - | 19.69% | 24.09% | 24.56% |
| FCF Conversion (EBITDA) | 0.58% | - | - | 44.29% | - | 49.67% | 59.93% | 58.7% |
| FCF Conversion (Net income) | - | - | - | 71.29% | - | 73.13% | 94.12% | 89.17% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 12/03/20 | 15/03/21 | 10/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 112.2 | 120.9 | 120.4 | 123.5 | 120.1 | 135 | 140 | 145.7 | 180.6 | 178.1 | 171.8 | 173.5 | 200.9 | 207.8 | 212 |
| EBITDA 1 | 34.44 | 31.15 | - | - | - | 49 | - | - | - | 80.5 | 68.4 | 70.02 | 85.59 | 80.79 | - |
| EBIT 1 | 15.5 | 25.75 | 21.64 | 24.82 | 27.92 | 42.47 | 41 | 48.01 | 89.16 | 67.67 | 58.48 | 56.76 | 69.78 | 70.98 | 70.4 |
| Operating Margin | 13.82% | 21.3% | 17.98% | 20.1% | 23.24% | 31.45% | 29.28% | 32.95% | 49.38% | 38% | 34.11% | 32.71% | 34.74% | 34.15% | 33.21% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | 51 | 70 | 67 | - |
| Net income 1 | 29.55 | 19.76 | - | - | - | 33.91 | - | - | - | - | 42.06 | 40 | 55 | 53 | - |
| Net margin | 26.34% | 16.35% | - | - | - | 25.12% | - | - | - | - | 24.54% | 23.05% | 27.38% | 25.5% | - |
| EPS 2 | - | - | 0.4700 | 0.3300 | 0.3000 | 0.6600 | - | 0.4900 | - | - | 0.9165 | 0.8195 | 1.036 | 0.9974 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 08/11/21 | 10/03/22 | 09/05/22 | 08/08/22 | 07/11/22 | 28/02/23 | 09/05/23 | 08/08/23 | 08/11/23 | 28/02/24 | 08/05/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 423 | 220 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | 10.6 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 1.418 x | 0.6492 x | - |
| Free Cash Flow 1 | 0.21 | - | - | 65.1 | - | 148 | 203 | 230 |
| ROE (net income / shareholders' equity) | - | - | - | - | 30.1% | 26.1% | 26.2% | 24.3% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | 12.9% | 12.5% | 13.1% |
| Assets 1 | - | - | - | - | - | 1,564 | 1,723 | 1,965 |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | - | 3.460 | 0.8100 | 4.310 | - |
| Capex 1 | 41.6 | 33.9 | 27.5 | 24 | 38.2 | 32.5 | 32.5 | 32.5 |
| Capex / Sales | 12.89% | 9.68% | 6.27% | 4.82% | 5.92% | 4.32% | 3.86% | 3.47% |
| Announcement Date | 12/03/20 | 15/03/21 | 10/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
42.21
USD
Average target price
62.6
USD
Spread / Average Target
+48.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.75% | 2.07B | |
| +30.38% | 695B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 330B | |
| +3.73% | 283B | |
| +16.70% | 239B | |
| +8.78% | 204B | |
| -7.93% | 198B | |
| +7.68% | 168B |
- Stock Market
- Equities
- AMPH Stock
- Financials Amphastar Pharmaceuticals, Inc.
